RESUMEN
PURPOSE: To evaluate, via a systematic review, the effectiveness of radiofrequency (RF) for treatment of primary hyperhidrosis (PH). METHODS: Experimental or observational studies were included where RF treatment (ablation or microneedling) was performed, comparing the periods before and after treatment. RESULTS: Nine studies were considered eligible and included for analysis. In seven of nine studies, patients were subjected to RF only, and in two of nine studies RF was compared to video-assisted thoracoscopic sympathectomy (VATS). There was a reduction in the severity of PH in microneedling (three studies, mean difference -1.24, 95% CI -1.44 to -1.03). In a study that performed sympathetic RF ablation there was a greater reduction in PH severity compared to studies that performed microneedling (-2.42, 95% CI -2.55 to -2.29). There was improvement in the quality of life (QoL) after sympathetic RF ablation (two studies, mean difference -15.92, 95% CI -17.61 to -14.24). Regarding the microneedling procedure, there was a lower improvement in QoL, (two studies, -9.0, 95% CI -9.15 to -8.85). One study comparing sympathetic RF ablation with VATS applied the QoL questionnaire, and the VATS showed superior results. One of the two studies comparing compensatory sweating in RF ablation with VATS showed that compensatory hyperhidrosis was higher in VATS; however, the other study did not observe this difference. One study compared the recurrence of symptoms between VATS and RF ablation; symptom recurrence was shown to be higher in RF. CONCLUSIONS: RF is effective for PH treatment, with superior results obtained with sympathetic ablation compared to microneedling.
Asunto(s)
Hiperhidrosis/diagnóstico , Hiperhidrosis/terapia , Terapia por Radiofrecuencia/métodos , Humanos , Hiperhidrosis/fisiopatología , Estudios Observacionales como Asunto/métodos , Satisfacción del Paciente , Terapia por Radiofrecuencia/tendencias , Simpatectomía/métodos , Simpatectomía/tendencias , Toracoscopía/métodos , Toracoscopía/tendencias , Resultado del TratamientoRESUMEN
Three recent renal denervation studies in both drug-naïve and drug-treated hypertensive patients demonstrated a significant reduction of ambulatory blood pressure compared with respective sham control groups. Improved trial design, selection of relevant patient cohorts, and optimized interventional procedures have likely contributed to these positive findings. However, substantial variability in the blood pressure response to renal denervation can still be observed and remains a challenging and important problem. The International Sympathetic Nervous System Summit was convened to bring together experts in both experimental and clinical medicine to discuss the current evidence base, novel developments in our understanding of neural interplay, procedural aspects, monitoring of technical success, and others. Identification of relevant trends in the field and initiation of tailored and combined experimental and clinical research efforts will help to address remaining questions and provide much-needed evidence to guide clinical use of renal denervation for hypertension treatment and other potential indications.
Asunto(s)
Monitoreo Ambulatorio de la Presión Arterial/tendencias , Congresos como Asunto/tendencias , Hipertensión/cirugía , Internacionalidad , Riñón/inervación , Simpatectomía/tendencias , Presión Sanguínea/fisiología , Desnervación/métodos , Desnervación/tendencias , Humanos , Hipertensión/diagnóstico , Hipertensión/fisiopatología , Riñón/fisiología , Ensayos Clínicos Controlados Aleatorios como Asunto/métodos , Literatura de Revisión como Asunto , Simpatectomía/métodos , Sistema Nervioso Simpático/fisiología , Sistema Nervioso Simpático/fisiopatologíaAsunto(s)
Hiperhidrosis/diagnóstico , Hiperhidrosis/etiología , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/etiología , Instrumentos Quirúrgicos/efectos adversos , Simpatectomía/efectos adversos , Humanos , Instrumentos Quirúrgicos/tendencias , Simpatectomía/tendencias , Factores de Tiempo , Resultado del TratamientoRESUMEN
The present paper is an extension to our earlier publication (Sochman et al. 2016) documenting a beneficial effect of renal sympathetic denervation on pharmacologically uncontrollable hypertension in a group of seven patients followed up for 1-2 years post-procedure. The same patients remained on ambulatory follow-up for another 5-6 years, with the beneficial effect persisting throughout the follow-up period while on the same medication.
Asunto(s)
Presión Sanguínea/fisiología , Hipertensión/cirugía , Riñón/fisiología , Riñón/cirugía , Simpatectomía/tendencias , Anciano , Antihipertensivos/uso terapéutico , Femenino , Estudios de Seguimiento , Humanos , Hipertensión/diagnóstico , Hipertensión/tratamiento farmacológico , Riñón/inervación , Masculino , Persona de Mediana Edad , Resultado del TratamientoAsunto(s)
Presión Sanguínea , Ablación por Catéter , Hipertensión/cirugía , Riñón/irrigación sanguínea , Arteria Renal/inervación , Simpatectomía/métodos , Antihipertensivos/uso terapéutico , Presión Sanguínea/efectos de los fármacos , Ablación por Catéter/efectos adversos , Ablación por Catéter/tendencias , Ensayos Clínicos como Asunto , Resistencia a Medicamentos , Predicción , Humanos , Hipertensión/diagnóstico , Hipertensión/fisiopatología , Simpatectomía/efectos adversos , Simpatectomía/tendencias , Resultado del TratamientoRESUMEN
BACKGROUND: Microvascular impairment is well documented in hypertension. We investigated the effect of renal sympathetic denervation (RDN) on cardiac and peripheral microvasculature in patients with treatment-resistant essential hypertension (TRH). METHODS: A randomized, single centre, double-blinded, sham-controlled clinical trial. Fifty-eight patients with TRH (ambulatory systolic BP (ASBP) ≥ 145mmHg) despite stable treatment were randomized to RDN or SHAM. RDN was performed with the unipolar Medtronic Flex catheter. Coronary flow reserve (CFR) and coronary- and forearm minimum vascular resistance (C-Rmin and F-Rmin) were determined using transthoracic Doppler echocardiography and F-Rmin with venous occlusion plethysmography at baseline and at six-months follow-up. RESULTS: RDN was performed with 5.3±0.2 lesions in the right renal artery and 5.4±0.2 lesions in the left. Baseline ASBP was 152±2mmHg (RDN, n=29) and 154±2mmHg (SHAM, n=29). Similar reductions in MAP were seen at follow up (-3.5±2.0 vs. -3.2±1.8, P=0.92). Baseline CFR was 2.9±0.1 (RDN) and 2.4±0.1 (SHAM), with no significant change at follow-up (0.2±0.2 vs. -0.1±0.2, P=0.57). C-Rmin was 1.9±0.3 (RDN) and 2.7±0.6 (SHAM) (mmHgmin/ml pr. 100g) and did not change significantly (0.3±0.5 vs. -0.4±0.8, P=0.48). F-Rmin was 3.6±0.2 (RDN) and 3.6±0.3 (SHAM) (mmHgmin/ml pr. 100ml tissue) and unchanged at follow-up (4.2±0.4 vs. 3.8±0.2, P=0.17). Left ventricular mass index was unchanged following RDN (-4±7 (RDN) vs. 3±5 (SHAM) (g/m2) P=0.38). CONCLUSION: The current study does not support positive effects of RDN on microvascular impairment in TRH.
Asunto(s)
Antebrazo/irrigación sanguínea , Reserva del Flujo Fraccional Miocárdico/fisiología , Hipertensión/cirugía , Riñón/inervación , Simpatectomía/tendencias , Vasodilatación/fisiología , Adulto , Anciano , Método Doble Ciego , Femenino , Estudios de Seguimiento , Humanos , Hipertensión/diagnóstico por imagen , Hipertensión/fisiopatología , Riñón/fisiopatología , Masculino , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
PURPOSE: Palmar hyperhidrosis (PH) is excessive sweating of the palms resulting from sympathetic overactivity, and patients who undergo endoscopic thoracic sympathectomy (ETS) show reduced cardiac demand after 1 year and improved cerebral perfusion within 2-4 weeks. However, the long-term risks of major adverse cardiovascular events (MACE) following ETS remain unclear. METHODS: We searched the Longitudinal National Health Insurance Database in Taiwan and identified PH patients (International Classification of Disease, Ninth Revision, Clinical Modification diagnostic code 708.8) from the outpatient database and patients who underwent ETS (procedure code 05.29) from the inpatient database between 2000 and 2010; furthermore, we excluded patients younger than 18 years of age or older than 65 years of age. We defined MACE as stroke (diagnostic codes 430-437), myocardial infarction (diagnostic code 410), or death. Patients followed until the first cardiac event or December 31, 2010. Risk factors were identified using a multivariable Cox proportional hazards regression. RESULTS: The incidence of MACE was significantly lower in patients with ETS (0.76%) than without (1.67%). In PH patients, ETS significantly reduced the risk of MACE (adjusted hazard ratio 0.473; 95% confidence interval 0.277-0.808). CONCLUSION: PH patients who underwent ETS showed a reduced risk of MACE over a long-term follow-up period. This result could provide support for patients with PH who are considering undergoing ETS because of its additional cardiovascular benefits.
Asunto(s)
Enfermedades Cardiovasculares/prevención & control , Endoscopía/tendencias , Mano/inervación , Hiperhidrosis/cirugía , Conducta de Reducción del Riesgo , Simpatectomía/tendencias , Adolescente , Adulto , Enfermedades Cardiovasculares/epidemiología , Bases de Datos Factuales/tendencias , Endoscopía/efectos adversos , Femenino , Estudios de Seguimiento , Humanos , Hiperhidrosis/epidemiología , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Simpatectomía/efectos adversos , Vértebras Torácicas , Adulto JovenRESUMEN
PURPOSE: Primary hyperhidrosis is a pathological disorder of unknown etiology, affecting 0.6-5% of the population, and causing severe functional and social handicaps. As the etiology is unknown, it is not possible to treat the root cause. Recently some differences between affected and non-affected people have been reported. The aim of this review is to summarize these new etiological data. METHODS: Search of the literature was performed in the PubMed/Medline Database and pertinent articles were retrieved and reviewed. Additional publications were obtained from the references of these articles. RESULTS: Some anatomical and pathophysiological characteristics (as well as enzymatic, metabolic, and neurological dysfunctions) have been observed in hyperhidrotic subjects; three main possible etiological factors predominate. A familial trait seems to exist, and genetic loci associated with hyperhidrosis have been identified. Histological differences were observed in sympathetic ganglia of hyperhidrotic subjects: the ganglia were larger and contained a higher number of ganglion cells. A higher expression of acetylcholine and alpha-7 neuronal nicotinic receptor subunit in the sympathetic ganglia of patients with hyperhidrosis has been reported. CONCLUSIONS: Despite these accumulated data, the etiology of primary hyperhidrosis remains obscure. Nevertheless, three main lines for future research seem to be delineated: genetics, histological observations, and enzymatic studies.
Asunto(s)
Ganglios Simpáticos/patología , Hiperhidrosis/etiología , Hiperhidrosis/patología , Animales , Humanos , Hiperhidrosis/genética , Simpatectomía/tendenciasRESUMEN
BACKGROUND: Heart failure (HF) is associated with chronic sympathetic activation. Renal denervation (RDN) aims to reduce sympathetic activity by ablating the renal sympathetic nerves. We investigated the effect of RDN in patients with chronic HF and concurrent renal dysfunction in a prospective, multicenter, single-arm feasibility study. METHODS AND RESULTS: Thirty-nine patients with chronic systolic HF (left ventricular ejection fraction [LVEF] <40%, New York Heart Association class II-III,) and renal impairment (estimated glomerular filtration rate [eGFR; assessed with the use of the Modification of Diet in Renal Disease equation] < 75 mL ⢠min-1 ⢠1.73 m-2) on stable medical therapy were enrolled. Mean age was 65 ± 11 years; 62% had ischemic HF. The average number of ablations per patient was 13 ± 3. No protocol-defined safety events were associated with the procedure. One subject experienced a renal artery occlusion that was possibly related to the denervation procedure. Statistically significant reductions in N-terminal pro-B-type natriuretic peptide (NT-proBNP; 1530 ± 1228 vs 1428 ± 1844 ng/mL; P = .006) and 120-minute glucose tolerance test (11.2 ± 5.1 vs 9.9 ± 3.6; P = .026) were seen at 12 months, but there was no significant change in LVEF (28 ± 9% vs 29 ± 11%; P= .536), 6-minute walk test (384 ± 96 vs 391 ± 97 m; P= .584), or eGFR (52.6 ± 15.3 vs 52.3 ± 18.5 mL ⢠min-1 ⢠1.73 m-2; P= .700). CONCLUSIONS: RDN was associated with reductions in NT-proBNP and 120-minute glucose tolerance test in HF patients 12 months after RDN treatment. There was no deterioration in other indices of cardiac and renal function in this small feasibility study.
Asunto(s)
Insuficiencia Cardíaca/diagnóstico por imagen , Insuficiencia Cardíaca/cirugía , Riñón/diagnóstico por imagen , Riñón/inervación , Simpatectomía/tendencias , Anciano , Estudios de Factibilidad , Femenino , Estudios de Seguimiento , Insuficiencia Cardíaca/sangre , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Simpatectomía/métodos , Factores de Tiempo , Resultado del TratamientoRESUMEN
One hundred years have elapsed since Thomas Jonnesco performed the first left cardiac sympathetic denervation (LCSD) in a patient with unmanageable angina pectoris and ventricular tachyarrhythmias, and the progress in the field has surpassed imagination. Here we will review the historic basis of cardiac sympathectomy for the management of life-threatening arrhythmias and will then discuss the often forgotten critical experimental studies that provided the rationale for the amazing growth of its role in clinical management. We will then mention the evolution in the surgical approaches, with their pros and cons. Similarly, we will address the existence of different views on the wisdom of starting with unilateral LCSD versus performing at outset bilateral CSD. The main results in the two diseases for which LCSD has already a definite role (namely the long QT syndrome and catecholaminergic polymorphic ventricular tachycardia) will be reviewed and discussed, touching also on the medico-legal implications descending from the clear efficacy of LCSD for these conditions. Finally, we will consider the potential value of LCSD for other clinical conditions and will close by mentioning a new randomized clinical trial in which LCSD is performed in patients with heart failure.
Asunto(s)
Corazón/inervación , Síndrome de QT Prolongado/cirugía , Simpatectomía/tendencias , Taquicardia Ventricular/cirugía , Corazón/fisiopatología , Humanos , Síndrome de QT Prolongado/diagnóstico , Síndrome de QT Prolongado/fisiopatología , Simpatectomía/métodos , Taquicardia Ventricular/diagnóstico , Taquicardia Ventricular/fisiopatologíaRESUMEN
Hypertension management poses a major challenge to clinicians globally once non-drug (lifestyle) measures have failed to control blood pressure (BP). Although drug treatment strategies to lower BP are well described, poor control rates of hypertension, even in the first world, suggest that more needs to be done to surmount the problem. A major issue is non-adherence to antihypertensive drugs, which is caused in part by drug intolerance due to side effects. More effective antihypertensive drugs are therefore required which have excellent tolerability and safety profiles in addition to being efficacious. For those patients who either do not tolerate or wish to take medication for hypertension or in whom BP control is not attained despite multiple antihypertensives, a novel class of interventional procedures to manage hypertension has emerged. While most of these target various aspects of the sympathetic nervous system regulation of BP, an additional procedure is now available, which addresses mechanical aspects of the circulation. Most of these new devices are supported by early and encouraging evidence for both safety and efficacy, although it is clear that more rigorous randomized controlled trial data will be essential before any of the technologies can be adopted as a standard of care.
Asunto(s)
Hipertensión/terapia , Antagonistas de Receptores de Angiotensina/uso terapéutico , Antihipertensivos/uso terapéutico , Derivación Arteriovenosa Quirúrgica/métodos , Derivación Arteriovenosa Quirúrgica/tendencias , Barorreflejo/fisiología , Ablación por Catéter/tendencias , Ensayos Clínicos como Asunto , Estimulación Encefálica Profunda/métodos , Estimulación Encefálica Profunda/tendencias , Venenos Elapídicos/agonistas , Medicina Basada en la Evidencia , Predicción , Humanos , Hipertensión/genética , Hipertensión/inmunología , Antagonistas de Receptores de Mineralocorticoides/uso terapéutico , Péptido Natriurético Tipo-C/agonistas , Neprilisina/antagonistas & inhibidores , Regeneración Nerviosa/fisiología , Norepinefrina/antagonistas & inhibidores , Péptidos/uso terapéutico , Sistema Renina-Angiotensina/fisiología , Simpatectomía/métodos , Simpatectomía/tendencias , Estimulación Eléctrica Transcutánea del Nervio/métodos , Estimulación Eléctrica Transcutánea del Nervio/tendencias , Péptido Intestinal Vasoactivo/uso terapéuticoRESUMEN
El fenómeno de Raynaud está causado por vasoespasmo de las pequeñas arterias y arteriolas de los dedos. Se desencadena por diversos estímulos, entre ellos la exposición al frío o un evento estresante. Puede ser simétrico o envolver una sola extremidad. La aparición de esta entidad en niños es muy infrecuente. Presentamos el caso de un varón de 4 años que consulta en su centro de salud por episodios de frialdad, palidez y dolor en ambos pies (AU)
Raynaud's Phenomenon is caused by spasm of the small arteries and arterioles of the fingers. It is triggered by various stimuli including exposure to cold or a stressful event. It may be symmetrical or wrap one end. The appearance of this entity in children is rare. We report the case of a 4 year old male consultation health center by episodes of coldness, pallor and pain in both feet (AU)
Asunto(s)
Humanos , Masculino , Preescolar , Enfermedad de Raynaud/complicaciones , Enfermedad de Raynaud/diagnóstico , Palidez/complicaciones , Palidez/diagnóstico , Cianosis/complicaciones , Angioscopía Microscópica/instrumentación , Angioscopía Microscópica/métodos , Vasoespasmo Coronario/complicaciones , Homocisteína , Dolor/complicaciones , Dolor/diagnóstico , Estudios de Cohortes , Simpatectomía/métodos , Simpatectomía/tendenciasRESUMEN
INTRODUCTION: Increased central sympathetic activity has a central role in the pathophysiology of cardiac arrhythmias. Despite the recently published negative results regarding the impact of renal sympathetic denervation (RDN) on resistant hypertension treatment, the beneficial effects of this intervention on cardiac arrhythmias seems to be promising. The aim of this systematic review is to analyze the existing data regarding the impact of RDN on atrial and ventricular arrhythmias. METHODS: We systematically searched MEDLINE/PubMed database until January 2016 by using the algorithm "renal denervation AND (arrhythmias OR atrial OR ventricular)" without limitations. Additionally, the reference lists of the included studies and the relevant review studies were also manually searched. RESULTS: Of the 467 studies yielded from the initial search, 34 were finally included in the systematic review (15 human studies, 18 animal studies and 1 study with both experimental and clinical data). The critical analysis of data from both human and animal studies indicates that RDN can modulate atrial and ventricular electrophysiological properties and exerts favorable effects in the development and recurrence of atrial and ventricular arrhythmias. CONCLUSION: In this systematic review we showed that RDN reduces the burden of atrial and ventricular arrhythmias in various experimental and clinical settings. Appropriately designed randomized sham controlled trials are needed in order to elucidate the exact impact of RDN on arrhythmia management.
Asunto(s)
Arritmias Cardíacas/cirugía , Riñón/inervación , Riñón/cirugía , Simpatectomía/tendencias , Sistema Nervioso Simpático/cirugía , Animales , Arritmias Cardíacas/fisiopatología , Humanos , Riñón/fisiopatología , Metaanálisis como Asunto , Ensayos Clínicos Controlados Aleatorios como Asunto/métodos , Simpatectomía/métodos , Sistema Nervioso Simpático/fisiopatologíaRESUMEN
The knowledge base for the continued development of catheter-based renal denervation is robust. A critical determinant of renal denervation success is the delivery of sufficient radiofrequency energy to both proximal and distal renal nerves, including in the renal artery divisions. New multielectrode catheters circumvent the several drawbacks of early models.
Asunto(s)
Ablación por Catéter/métodos , Ablación por Catéter/tendencias , Hipertensión/cirugía , Riñón/inervación , Arteria Renal/inervación , Simpatectomía/tendencias , Sistema Nervioso Simpático/cirugía , Presión Sanguínea , Ensayos Clínicos Controlados como Asunto , HumanosAsunto(s)
Hipertensión/cirugía , Hipertrofia Ventricular Izquierda/cirugía , Insuficiencia Renal Crónica/cirugía , Simpatectomía , Anciano , Femenino , Humanos , Hipertensión/diagnóstico , Hipertrofia Ventricular Izquierda/diagnóstico , Masculino , Persona de Mediana Edad , Insuficiencia Renal Crónica/diagnóstico , Simpatectomía/tendencias , Resultado del TratamientoRESUMEN
Resistant hypertension remains a growing problem worldwide. Renal sympathetic denervation was thought to be a new method for the treatment for resistant hypertension. Early studies demonstrated a marked benefit in patients who underwent renal denervation procedures, but the pivotal SYMPLICITY 3-HTN trial, the only sham-controlled randomized trial performed, did not show a benefit for patients treated with the procedure compared to sham. There is still much to learn about the physiology and anatomy of renal sympathetic pathways as well as careful attention to medication adherence in order to understand the role of renal sympathetic denervation in treating hypertensive patients. While renal denervation technology remains available in clinical practice outside of the USA, we expect further development of this technology in the upcoming years and the continued evaluation of this technology in patients with hypertension as well as other disease states to fully understand its role.
Asunto(s)
Ablación por Catéter/métodos , Hipertensión/terapia , Riñón/inervación , Arteria Renal/fisiopatología , Simpatectomía/métodos , Antihipertensivos/uso terapéutico , Ablación por Catéter/tendencias , Humanos , Hipertensión/fisiopatología , Ensayos Clínicos Controlados Aleatorios como Asunto , Simpatectomía/tendenciasRESUMEN
Hypertension remains a leading cause of cardiovascular morbidity and mortality worldwide. It is estimated that 12.8% of hypertensive adults have resistant hypertension. The sympathetic nervous system is a well-known contributor to the pathophysiology of resistant hypertension. Renal denervation has emerged as an effective procedure to treat resistant hypertension by blocking the sympathetic nervous system. The medical device industry has developed various catheters in an effort to achieve better denervation in the absence of available testing to document adequate denervation. By adding a sham control group to the study design, researchers found that the results of the Renal Denervation in Patients With Uncontrolled Hypertension study (SYMPLICITY HTN-3) showed that renal denervation was not superior to placebo in decreasing systolic blood pressure. Although SYMPLICITY HTN-3 successfully addressed many issues that might have biased the previously published data, incomplete denervation caused by limited operator experience, catheter design, and the radiofrequency ablation technology may have accounted for the discrepancy of the results. This, along with differences in the study design and population, should direct future renal denervation studies. This article reviews the available literature and proposes future directions for renal denervation studies. It also provides a detailed comparison of the available catheters and their respective clinical data.
Asunto(s)
Presión Sanguínea , Ablación por Catéter , Hipertensión/cirugía , Riñón/irrigación sanguínea , Simpatectomía , Animales , Ablación por Catéter/efectos adversos , Ablación por Catéter/historia , Ablación por Catéter/instrumentación , Ablación por Catéter/tendencias , Catéteres , Difusión de Innovaciones , Diseño de Equipo , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Hipertensión/diagnóstico , Hipertensión/historia , Hipertensión/fisiopatología , Complicaciones Posoperatorias/etiología , Factores de Riesgo , Simpatectomía/efectos adversos , Simpatectomía/historia , Simpatectomía/instrumentación , Simpatectomía/tendencias , Resultado del TratamientoRESUMEN
Previous preclinical and clinical studies provide insight into the mechanisms that account for the chronic lowering of blood pressure (BP) during suppression of central and peripheral sympathetic outflow. From these mechanisms, novel and alternative approaches to BP control in patients with hypertension resistant to medical therapy have been proposed. Over the past 5 years, data from prospective cohorts and randomized studies showed that renal denervation therapy is a safe procedure associated with a significant reduction of office BP but only a modest reduction in ambulatory BP despite intensive ongoing medical therapy. Recently, the failure of the most rigourously designed randomized study, SYMPLICITY HTN-3, to meet its primary efficacy end point has raised several questions and unresolved methodological issues. Further prospective randomized controlled trials are required to further assess the efficacy, durability, and cost-effectiveness of renal denervation therapy and its effects on cardiovascular and renal outcomes in carefully selected patients with true treatment-resistant hypertension.
Asunto(s)
Antihipertensivos/uso terapéutico , Resistencia a Medicamentos , Hipertensión/cirugía , Riñón/inervación , Simpatectomía/métodos , Antihipertensivos/efectos adversos , Femenino , Estudios de Seguimiento , Predicción , Humanos , Hipertensión/diagnóstico , Hipertensión/tratamiento farmacológico , Riñón/cirugía , Masculino , Evaluación de Necesidades , Seguridad del Paciente , Selección de Paciente , Ensayos Clínicos Controlados Aleatorios como Asunto , Medición de Riesgo , Índice de Severidad de la Enfermedad , Simpatectomía/tendencias , Sistema Nervioso Simpático/cirugía , Resultado del TratamientoRESUMEN
Varied causative and risk factors can lead to cardiac dysfunction. Cardiac dysfunction often evolves into heart failure by cardiac remodeling due to autonomic nervous system disturbance and neurohumoral abnormalities, even if the detriment factors are removed. Renal sympathetic nerve activity plays a pivotal regulatory role in neurohumoral mechanisms. The present study was designed to determine the therapeutic effects of renal sympathetic denervation (RSD) on cardiac dysfunction, fibrosis, and neurohumoral response in transverse aortic constriction (TAC) rats with chronic pressure overload. The present study demonstrated that RSD attenuated myocardial fibrosis and hypertrophy, and structural remodeling of the left atrium and ventricle, up-regulated cardiac beta adrenoceptor (beta-AR, including beta(1)AR and beta(2)AR) and sarco-endoplasmic reticulum Ca(2+)-ATPase (SERCA) while down-regulated angiotensin II type 1 receptor (AT(1)R), and decreased plasma B-type natriuretic peptide (BNP), norepinephrine (NE), angiotensin II (Ang II), and arginine vasopressin (AVP) levels in TAC rats with chronic pressure overload. We conclude that RSD attenuates myocardial fibrosis, the left atrial enlargement, and the left ventricular wall hypertrophy; inhibits the overdrive of the sympathetic nervous system (SNS), renin-angiotensin-aldosterone system (RAAS), and AVP system in TAC rats with chronic pressure overload. RSD could be a promising non-pharmacological approach to control the progression of cardiac dysfunction.